Glioblastoma — frontier options in Texas
30 open options
- TRIALPHASE1 / PHASE2RECRUITING
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Debio 0123 · Temozolomide · Radiotherapy — 16 sites
- TRIALPHASE2RECRUITING
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
ACT001 — 20 sites
- TRIALPHASE2RECRUITING
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Temozolomide · Neratinib · QBS10072S — 12 sites
- TRIALPHASE1 / PHASE2RECRUITING
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
TNG456 · abemaciclib — 15 sites
- TRIALPHASE1RECRUITING
GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma
15.GPC3-CAR T cells — 1 site
- TRIALPHASE4RECRUITING
Dabrafenib and/or Trametinib Rollover Study
dabrafenib · trametinib — 33 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
Biopsy Procedure · Magnetic Resonance Imaging · Radiation Therapy — 127 sites
- TRIALPHASE1 / PHASE2RECRUITING
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
ADV/HSV-tk (gene therapy) — 1 site
- TRIALPHASE1RECRUITING
A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma
NK Cells · NK Cells — 1 site
- TRIALPHASE1RECRUITING
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
Everolimus · Trametinib — 17 sites
- TRIALPHASE3RECRUITING
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
SonoCloud-9 (SC9) · Carboplatin · Lomustine — 55 sites
- TRIALPHASE2RECRUITING
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
DOC1021 · Tumor resection · Temodar (Temozolomide) — 18 sites
- TRIALNARECRUITING
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
Educational Intervention · Questionnaire Administration · Survey Administration — 1 site
- TRIALPHASE1RECRUITING
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
G207 — 3 sites
- TRIALPHASE1RECRUITING
C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)
C7R-GD2.CART cells (IV and ICV infusion) · C7R-GD2.CART cells (IV and ICV infusion) — 1 site
- TRIALPHASE2RECRUITING
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
PEP-CMV · Temozolomide · Tetanus Diphtheria Vaccine — 13 sites
- TRIALPHASE2NOT_YET_RECRUITING
FG001 Near-Infrared Fluorescence Imaging During Tumor Resection in Newly Diagnosed High-Grade Glioma
FG001 — 5 sites
- TRIALPHASE1RECRUITING
Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)
203Pb-RMX-VHPIB injection · SPECT/CT Imaging — 1 site
- TRIALEARLY_PHASE1RECRUITING
A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
Larotrectinib · Larotrectinib surgical — 21 sites
- TRIALPHASE2RECRUITING
Sacituzumab Govitecan in Recurrent Glioblastoma
Sacituzumab Govitecan — 3 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
LCB84 · Anti-PD-1 monoclonal antibody — 8 sites
- TRIALPHASE1 / PHASE2NOT_YET_RECRUITING
NG101m Adjuvant Therapy in Glioblastoma Patients
Intensity-modulated radiation therapy · Temozolomide · NG101m — 1 site
- TRIALPHASE1RECRUITING
Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment
Retreatment Rhenium Liposome — 1 site
- TRIALPHASE1RECRUITING
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
Eflornithine (Dose Level 1) · Eflornithine (Dose Level 2) · Eflornithine (Dose Level -1) — 8 sites
- EXPANDED ACCESSAVAILABLE
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
Ulixertinib (BVD-523) — 26 sites
- TRIALPHASE2RECRUITING
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
Lomustine · Imipramine Hydrochloride — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
ADV/HSV-tk (gene therapy) — 1 site
- TRIALPHASE1RECRUITING
Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM
Cord Blood-derived Expanded Allogeneic Natural Killer Cells · Resection — 1 site
- TRIALPHASE2RECRUITING
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
BMS-986504 · Daraxonrasib · Nivolumab + Relatlimab FDC — 57 sites
- TRIALPHASE2RECRUITING
Study of Olutasidenib and Temozolomide in HGG
Olutasidenib + TMZ — 20 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.